Document Detail

Examining treatment of ST-elevation myocardial infarction: the importance of early intervention.
MedLine Citation:
PMID:  20061507     Owner:  NLM     Status:  MEDLINE    
Early reperfusion in ST-segment elevation myocardial infarction (STEMI) is imperative. Acute reperfusion may be achieved with fibrinolytic agents and/or percutaneous coronary intervention (PCI); however, PCI is associated with lower rates of death and myocardial infarction compared with fibrinolysis. As treatment delays are associated with worse outcomes, current guidelines recommend minimizing time from symptom onset to treatment initiation. Regardless of the reperfusion strategy, patients with STEMI are at increased risk of early recurrent ischemic events and death. These risks can be significantly reduced by promptly initiating a combination of pharmacotherapies that includes antiplatelet and anticoagulant agents, beta-blockers, and inhibitors of the renin-angiotensin-aldosterone system. This manuscript reviews the evidence supporting the most recent guidelines for STEMI management published jointly by the American College of Cardiology and American Heart Association. More recent evidence and its potential impact on future evidence-based guidelines are also addressed.
Gervasio A Lamas; Esteban Escolar; David P Faxon
Related Documents :
23439987 - Troponin testing after cardiac surgery.
17453137 - Percutaneous coronary interventions in europe: prevalence, numerical estimates, and pro...
22952697 - Analyses of the redistribution of work following cardiac resynchronisation therapy in a...
24772257 - High-sensitivity cardiac troponins in everyday clinical practice.
3941367 - Separate effects of ischemia, hypoxia, and contractility on thallium-201 kinetics in ra...
2521367 - Early and five-year results for coronary artery bypass grafting. a benchmark for percut...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-01-08
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  15     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-05     Completed Date:  2010-04-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  6-16     Citation Subset:  IM    
Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome
Adrenergic beta-Antagonists / therapeutic use
Fibrinolytic Agents / therapeutic use*
Myocardial Infarction / therapy*
Myocardial Reperfusion / methods*
Platelet Aggregation Inhibitors / therapeutic use
Practice Guidelines as Topic
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Microbacterium radiodurans sp. nov., a UV radiation-resistant bacterium isolated from soil.
Next Document:  The Falls Efficacy Scale International (FES-I). A comprehensive longitudinal validation study.